Conavi Medical Corp. CNVIF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -90.74% | -91.78% | -92.98% | 309.93% | 144.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.74% | -91.78% | -92.98% | 309.93% | 144.62% |
| Cost of Revenue | -98.25% | -98.55% | -101.62% | -31.01% | -17.37% |
| Gross Profit | -88.77% | -89.54% | -89.17% | 13,628.72% | 403.34% |
| SG&A Expenses | 28.96% | 3.15% | -8.18% | -15.43% | -11.75% |
| Depreciation & Amortization | -0.13% | -11.22% | -15.98% | -19.90% | -21.91% |
| Other Operating Expenses | 2.58% | 2.58% | 13.09% | -15.61% | -23.57% |
| Total Operating Expenses | -11.83% | -31.94% | -33.56% | -17.88% | -16.64% |
| Operating Income | -33.58% | 3.92% | 5.45% | 44.93% | 39.57% |
| Income Before Tax | 30.76% | 54.63% | 63.23% | 54.06% | 15.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.76% | 54.63% | 63.23% | 54.06% | 15.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.76% | 54.63% | 63.23% | 54.06% | 15.36% |
| EBIT | -33.58% | 3.92% | 5.45% | 44.93% | 39.57% |
| EBITDA | -34.33% | 3.83% | 5.25% | 45.62% | 39.85% |
| EPS Basic | 92.08% | 95.55% | 96.04% | 95.07% | 53.23% |
| Normalized Basic EPS | 86.37% | 93.30% | 94.62% | 95.86% | 70.85% |
| EPS Diluted | 92.08% | 95.55% | 96.04% | 95.07% | 53.23% |
| Normalized Diluted EPS | 86.37% | 93.30% | 94.62% | 95.86% | 70.85% |
| Average Basic Shares Outstanding | 124.64% | 233.42% | 355.23% | 913.42% | 600.89% |
| Average Diluted Shares Outstanding | 124.64% | 233.42% | 355.23% | 913.42% | 600.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |